CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 6, 2004, Pages 529-538

  Wong, Mark ^a   Balleine, Rosemary L ^b   Collins, Michael ^b   Liddle, Christopher ^b   Clarke, Christine L ^b   Gurney, Howard ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A5; MIDAZOLAM;

ADULT; AGED; ALLELE; ANALYSIS OF VARIANCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; GENOTYPE; HETEROZYGOSITY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; AUSTRALIA; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGED; NEOPLASMS;

EID: 2942560581     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.02.005     Document Type: Article

References (39)

1. Gurney H. Dose calculation of anticancer drugs a review of the current practice and introduction of an alternative. J Clin Oncol. 14:1996;2590-2611
2. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 86:2002;1297-1302
3. Relling M.V., Nemec J., Schuetz E.G., Schuetz J.D., Gonzalez F.J., Korzekwa K.R. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 45:1994;352-358
4. Marre F., Sanderink G.J., de Sousa G., Gaillard C., Martinet M., Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro involvement of the CYP3A subfamily in humans. Cancer Res. 56:1996;1296-1302
5. Toffoli G., Cecchin E., Corona G., Boiocchi M. Pharmacogenetics of irinotecan. Curr Med Chem Anti-Canc Agents. 3:2003;225-237
6. Zhou-Pan X.R., Seree E., Zhou X.J., Placidi M., Maurel P., Barra Y., et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism drug interactions. Cancer Res. 53:1993;5121-5126
7. Zhou X.J., Zhou-Pan X.R., Gauthier T., Placidi M., Maurel P., Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol. 45:1993;853-861
8. Lin Y.S., Dowling A.L., Quigley S.D., Farin F.M., Zhang J., Lamba J., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 62:2002;162-172
9. Thummel K.E., Shen D.D., Podoll T.D., Kunze K.L., Trager W.F., Bacchi C.E., et al. Use of midazolam as a human cytochrome P450 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther. 271:1994;557-566
10. Lin Y.S., Lockwood G.F., Graham M.A., Brian W.R., Loi C.M., Dobrinska M.R., et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 11:2001;781-791
11. Goodwin B., Redinbo M.R., Kliewer S.A. Regulation of Cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol. 42:2002;1-23
12. Gellner K., Eiselt R., Hustert E., Arnold H., Koch I., Haberl M., et al. Genomic organization of the human CYP3A locus identification of a new, inducible CYP3A gene. Pharmacogenetics. 11:2001;111-121
13. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 54:2002;1271-1294
14. Lamba J.K., Lin Y.S., Thummel K., Daly A., Watkins P.B., Strom S., et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 12:2002;121-132
15. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 27:2001;383-391
16. Thummel K.E. Does the CYP3A5*3 polymorphism affect in vivo drug elimination? Pharmacogenetics. 13:2003;585-587
17. Du Bois D., Du Bois E.F. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 5:1989;303-311
18. Gorski J.C., Hall S.D., Jones D.R., Vandenbranden M., Wrighton S.A. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 47:1994;1643-1653
19. Kronbach T., Mathys D., Umeno M., Gonzalez F.J., Meyer U.A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 36:1989;89-96
20. Fraser A.D., Bryan W., Isner A.F. Urinary screening for midazolam and its major metabolites with the Abbott ADx and TDx analyzers and the EMIT d.a.u. benzodiazepine assay with confirmation by GC/MS. J Anal Toxicol. 15:1991;8-12
21. Fabre G., Crevat-Pisano P., Dragna S., Covo J., Barra Y., Cano J.P. Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochem Pharmacol. 37:1988;1947-1953
22. Fabre G., Rahmani R., Placidi M., Combalbert J., Covo J., Cano J.P., et al. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol. 37:1988;4389-4397
23. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 16:1999;408-414
24. Thummel K.E., O'Shea D., Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 59:1996;491-502
25. Floyd M.D., Gervasini G., Masica A.L., Mayo G., George A.L. Jr, Bhat K., et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 13:2003;595-606
26. Strain G.W., Zumoff B. The relationship of weight-height indices of obesity to body fat content. J Am Coll Nutr. 11:1992;715-718
27. Johnston D.E. Special considerations in interpreting liver function tests. Am Fam Physician. 59:1999;2223-2230
28. Robert J., Vrignaud P., Nguyen-Ngoc T., Iliadis A., Mauriac L., Hurteloup P. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep. 69:1985;633-640
29. Soininen K., Kleimola T., Elomaa I., Salmo M., Rissanen P. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients. J Int Med Res. 14:1986;162-165
30. Grieco A., Castellano R., Matera A., Marcoccia S., Di Rocco P., Ragazzoni E., et al. Antipyrine clearance in chronic and neoplastic liver diseases a study of 518 patients. J Gastroenterol Hepatol. 13:1998;460-466
31. Grieco A., Barone C., Coletta P., Castellano R., Ragazzoni E., Cassano A., et al. Antipyrine metabolism in patients with liver metastases from colorectal cancer. Cancer. 70:1992;1477-1482
32. Givens R.C., Lin Y.S., Dowling A.L., Thummel K.E., Lamba J.K., Schuetz E.G., et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 95:2003;1297-1300
33. Thervet E., Anglicheau D., King B., Schlageter M.H., Cassinat B., Beaune P., et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 76:2003;1233-1235
34. Westlind-Johnsson A., Malmebo S., Johansson A., Otter C., Andersson T.B., Johansson I., et al. Comparative analysis of Cyp3a expression in human liver suggests only a minor role for Cyp3a5 in drug metabolism. Drug Metab Dispos. 31:2003;755-761
35. Goh B.C., Lee S.C., Wang L.Z., Fan L., Guo J.Y., Lamba J., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 20:2002;3683-3690
36. Shih P.S., Huang J.D. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos. 30:2002;1491-1496
37. Chou F.C., Tzeng S.J., Huang J.D. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos. 29:2001;1205-1209
38. Evans W.E., McLeod H.L. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 348:2003;538-549
39. Nagasubramanian R., Innocenti F., Ratain M.J. Pharmacogenetics in cancer treatment. Annu Rev Med. 54:2003;437-452